Advertisement Article continues below this ad "New York ... for Regeneron, which is one of the fastest-growing manufacturers in the Capital Region with 2,500 employees in East Greenbush and ...

Regeneron, which is headquartered in Tarrytown but does its manufacturing in East Greenbush ... and investigative journalism from the New York State Associated Press Association and the New ...

Regeneron is awaiting final approval from the East Greenbush town board to construct a new office building. Drug developer Regeneron Pharmaceuticals Inc. plans to add 70,000 square feet of office ...

It is the latest in a string of investments that Regeneron has made throughout Rensselaer County. Regeneron Pharmaceuticals has acquired a 74,000-square-foot office building in the East Greenbush ...

This announcement would mark the largest growth for the industry in New York state ... at Regeneron’s East Greenbush location. They include a new 65,000 square foot building at 81 Columbia ...

That project will include building a ... Incentives from New York state will fund $140 million in improvements, Regeneron said. The second phase of the East Greenbush expansion was announced ...

Drugmaker Regeneron ... it is building in New York. The company is spending $72 million on a new 65,000-square-foot plant and another $7.5 million for administrative offices in East Greenbush ...

EAST GREENBUSH — With smiles and golden shovels, local officials and representatives from Regeneron Pharmaceuticals ... Manufacturing jobs in New York State have dropped dramatically in the ...

Drug company Regeneron Pharmaceuticals has announced a $40 million investment projected to create more than 300 jobs in New York state, including up to 100 in Rensselaer County. The jobs follow an ...

EAST GREENBUSH ... Development offered Regeneron up to $140 million in performance-based incentives, including $70 million in Excelsior Jobs Program tax credits. "New York is proud to be at ...

EAST GREENBUSH NY (WRGB) - Bio-tech company Regeneron, which has a big work force here in the Capital Region, has confirmed that phase three trials are in the works for a combination antibody ...